Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

Core Insights - Nektar Therapeutics will host an investor call and live webcast to review topline results from the 36-week induction treatment period in the ongoing Phase 2b REZOLVE-AA clinical trial of rezpegaldesleukin for severe-to-very-severe alopecia areata on December 16, 2025 [1] Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [3] - The lead product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one for atopic dermatitis and one for alopecia areata, as well as in a Phase 2 clinical trial for Type 1 diabetes mellitus [3] - Nektar's pipeline includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422 [3] - The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to enhance the immune system's ability to combat cancer, in several ongoing clinical trials [3] Event Details - The results from the clinical trial will be provided in a morning press release and presented during the webcast, which can be accessed via a provided link [2] - A replay of the webcast will be available for at least 30 days following the event [2]